THERE ARE CURRENTLY NO SPECIFIC TREATMENTS FOR COVID-19. THE DEVELOPMENT OF A VACCINE Ê BY DEFINITION THE APPROACH OF ELECTION AGAINST INFECTIOUS DISEASES. AN ALTERNATIVE APPROACH IS THE USE OF LABORATORY SYNTHESISED MONOCLONAL ANTIBODIES THAT MIMIC NATURAL ANTIBODIES. ANTIBODIES-BASED TREATMENT, AIMED AT NEUTRALISING SARS-COV-2 VIRUS INFECTION, CAN BE APPLIED BOTH IN PREVENTION AND TO TREAT AND PREVENT DISEASE PROGRESSION IN ALREADY INFECTED PATIENTS. SUCH TREATMENT WOULD HAVE THE POSSIBILITY OF HAVING AN IMMEDIATE EFFECT ON THE PATIENT. THE BLOOD OF SUBJECTS VACCINATED OR HEALED FROM INFECTION AND ONE OF THE BEST SOURCES OF NEUTRALISING ANTIBODIES (CUTINO-MOGUEL ET AL, BR J HAEMATOL 2017, DOI:10.1111/BJH.14595; HEDGE ET AL, IMMUNOTHERAPY 2009, DOI:10.2217/IMT.09.26), BUT SUFFERS FROM SEVERE LIMITATIONS (LIMITED QUANTITY, HIGH VARIABILITY, NON-REPRODUCIBILITY AND POTENTIAL INFECTIOUS RISK OF PLASMA DE